Cymbalta (duloxetine) isn’t inherently “bad for you,” but it does carry real risks and side effects that matter. Like most antidepressants, it’s a trade-off: genuine therapeutic benefits for several conditions weighed against side effects that range from mildly annoying to, in rare cases, serious. Whether those trade-offs make sense depends on what you’re taking it for, how your body responds, and how long you stay on it.
What Cymbalta Is Prescribed For
Cymbalta works by increasing levels of two brain chemicals (serotonin and norepinephrine) that affect mood and pain signaling. It’s FDA-approved for major depression, generalized anxiety disorder, diabetic nerve pain, fibromyalgia, and chronic musculoskeletal pain. That’s an unusually wide range of uses for a single medication, which is part of why so many people take it and why questions about its safety come up so often.
Most adults start at 30 to 60 mg per day, with doses occasionally going up to 120 mg. Effects aren’t immediate. In clinical trials, patients on 60 mg typically saw a meaningful 20% improvement in depression scores after about three weeks, though some noticed smaller changes within the first two weeks.
Common Side Effects
The most frequent complaints are nausea, drowsiness, insomnia, and dizziness, each affecting roughly 10 to 20 percent of patients. Dry mouth and constipation also show up regularly. For many people, nausea is worst in the first week or two and then fades. Drowsiness and dizziness tend to follow a similar pattern, though not always.
These side effects are the main reason people stop taking Cymbalta early. They’re not dangerous in most cases, but they can be disruptive enough to make you question whether the medication is worth it, especially before the therapeutic benefits have had time to kick in.
Sexual Side Effects
This is one of the biggest concerns people have, and the numbers back it up. In a study of patients with recurrent depression, nearly three-quarters already met criteria for sexual dysfunction before starting treatment (depression itself is a major cause). But among those who entered the study without sexual problems, about a third developed new sexual dysfunction while on duloxetine.
Women are disproportionately affected. In that same study, only 16% of women did not meet criteria for sexual dysfunction at the start. For patients whose depression responded well to treatment, the rate of continued sexual problems dropped to about 53%, compared to nearly 78% for those who didn’t respond. In other words, when Cymbalta works well for your mood, your sexual function is more likely to recover too, but there are no guarantees.
Weight Changes
Cymbalta’s effect on weight follows a two-phase pattern. In the short term (the first several weeks), most people lose a small amount of weight, likely because of the nausea. Over the longer term, weight creeps back up. In a 52-week study, patients on duloxetine gained an average of about 1.1 kg (roughly 2.4 pounds). At a higher dose of 120 mg daily over 34 weeks, patients gained about 0.9 kg compared to almost no change in the placebo group. That’s modest compared to some other antidepressants, but it’s not zero.
Liver Health
This is where the risk profile gets more serious for certain people. In clinical trials, about 10.6% of patients on duloxetine showed elevated liver enzyme levels on blood tests, compared to 7.7% on placebo. Most of these elevations were small and didn’t cause symptoms. However, a small number of patients developed significant liver enzyme spikes (more than ten times the normal upper limit), and three male patients with a history of heavy alcohol use developed liver injury with jaundice.
The FDA specifically recommends against using Cymbalta if you drink heavily or have a history of alcohol abuse, because alcohol appears to amplify the risk of liver damage. People with pre-existing liver disease need close monitoring with regular blood tests if they take this medication.
The Black Box Warning on Suicide Risk
Cymbalta carries the FDA’s most serious warning: a black box label about increased suicidal thinking in young people. The data breaks down clearly by age. In patients under 18, there were 14 additional cases of suicidal thoughts or behavior per 1,000 patients treated, compared to placebo. For ages 18 to 24, there were 5 additional cases per 1,000. Adults 25 to 64 actually had one fewer case per 1,000, and adults 65 and older had six fewer cases per 1,000.
No suicides occurred in any of the pediatric trials, and the adult trial numbers were too small to draw firm conclusions about completed suicide. The risk is concentrated in the early weeks of treatment and during dose changes, which is why close monitoring matters most during those periods. This warning applies to all antidepressants in this class, not just Cymbalta specifically.
Withdrawal Can Be Rough
If there’s one area where Cymbalta has a particularly bad reputation, it’s discontinuation. Stopping the medication, especially abruptly, can trigger withdrawal symptoms within a day or two. Common symptoms include nausea, headache, anxiety, dizziness, irritability, and what patients often describe as “brain zaps,” brief electrical-sensation-like jolts in the head.
These symptoms can last anywhere from a few days to several weeks, and in some cases months. The severity varies widely from person to person. Gradual tapering, slowly reducing the dose over time, is the standard approach to minimize withdrawal. This is not a medication you should stop cold turkey. If you’re considering coming off Cymbalta, plan the process with your prescriber and expect it to take longer than you might think.
Who Should Avoid Cymbalta
Certain groups face higher risk. Heavy drinkers and people with liver disease are at elevated risk for liver injury. Cymbalta should not be taken alongside a class of older antidepressants called MAOIs, as the combination can cause a dangerous reaction called serotonin syndrome (a buildup of serotonin that can cause rapid heart rate, high blood pressure, and confusion). You also need to be cautious combining it with other medications that raise serotonin levels.
For people under 25, the increased risk of suicidal thoughts needs to be weighed carefully against the severity of the condition being treated. That calculus is different for someone with mild anxiety versus someone with severe, treatment-resistant depression.
Putting the Risks in Context
Cymbalta is not uniquely dangerous among antidepressants. Its side effect profile is broadly similar to other medications in the same class. Where it stands out is in the difficulty some people have stopping it and in the liver risk for drinkers. For the conditions it treats, particularly nerve pain and fibromyalgia alongside depression, it fills a niche that few other single medications cover.
The people who do best on Cymbalta tend to be those who tolerate the initial side effects (especially nausea), don’t drink heavily, and plan ahead for eventual discontinuation. The people who have the worst experiences are often those who weren’t warned about withdrawal, who stop abruptly, or who have risk factors like liver problems that should have been flagged before starting.